A number of the adverse events reported during the clinical investigations and postmarketing experience with Loperamide are frequent symptoms of the underlying diarrheal syndrome (abdominal pain/discomfort, nausea, vomiting, dry mouth, tiredness, drowsiness, dizziness, constipation, and flatulence). These symptoms are often difficult to distinguish from undesirable drug effects.
Indication
Diarrhea.
Contra Indication on Acute diarrhea associated with the entry of organisms through the intestinal mucosa orpseudomembranous colitis associated with broad-spectrum antibiotics.
Baby.
Caution
Discontinue use if within 48 hours of no change.
Children under 2 years old.
Liver dysfunction.
Inflammatory bowel disease.
Side Effect
Abdominal pain, toxic megacolon, dry mouth, dizziness, fatigue, redness of the skin.
Caution :
B: Neither animal reproductive studies show no risk to the fetus as well as controlled studies in pregnant women or experimental animals showed no adverse effects (except for a decrease in fertility) where there are no controlled studies that confirm the risk in the first half of pregnant women (and no evidence of risk to the trimester hereinafter).
Packaging
Film-coated tablets 2 mg x 60 points.
Dosage
Adults: initial dose of 2 tablets and 1 tablet after each bowel movement.
Children: 100 mcg / kg body weight.
Maximum of 4-6 tablets per day.
Presentation
Taken with food or not
Composition
Loperamide HCl.
References
|
|
Chumakova YA, Bashkatova VG, Sudakov SK
Changes in feeding behavior after peripheral loperamide administration in rats. [Journal Article, Research Support, Non-U.S. Gov't]
Bull Exp Biol Med 2011 Feb; 150(4):398-400.
Abstract | Full Citation | |
|
Lee HY, Kim JH, Jeung HW, et al.
Effects of Ficus carica paste on loperamide-induced constipation in rats. [Journal Article]
Food Chem Toxicol 2012 Mar; 50(3-4):895-902.
Abstract | Full Citation | Publisher Full Text | |
|
Zhou Y, Sridhar R, Shan L, et al.
Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity. [Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.]
Cancer Invest 2011 Feb; 30(2):119-25. |